14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NAMS vs TLX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over NewAmsterdam Pharma Company N.V. (NAMS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NAMS carries a Unified Composite Score of 44.5/100 (HOLD) at $19.74 (108.7x Forward P/E, -900.1% operating margin), whereas TLX carries 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin).
Growth vs. Quality Trade-Off: TLX earns the overall head-to-head edge with a stronger Unified Composite Score (46.4/100 HOLD vs. NAMS 44.5/100 HOLD) and 0.84β · 62% Vol risk profile, whereas NAMS leads top-line expansion (+5406.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NAMS is currently in a Breakdown options structure phase (RSI 45.2); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NAMS vs TLX. Trailing 12-month operating profitability (NAMS -900.1% vs TLX 6.2%) and valuation multiples (NAMS 108.7x vs TLX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment41.4% of Rev ($369M)
90D Engineering Disclosures0 Published
Investor FAQ NAMS vs TLX Key Questions & Quantitative Answers
As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over NewAmsterdam Pharma Company N.V. (NAMS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NAMS carries a Unified Composite Score of 44.5/100 (HOLD) at $19.74 (108.7x Forward P/E, -900.1% operating margin), whereas TLX carries 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin). Growth vs. Quality Trade-Off: TLX earns the overall head-to-head edge with a stronger Unified Composite Score (46.4/100 HOLD vs. NAMS 44.5/100 HOLD) and 0.84β · 62% Vol risk profile, whereas NAMS leads top-line expansion (+5406.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NAMS is currently in a Breakdown options structure phase (RSI 45.2); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TLX leads the Growth & Scale pillar: NAMS posts +5406.9% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (100.0% gross margin, -900.1% operating margin), compared with TLX at +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin). On trailing 12-month operating scale, NAMS generates $26M in USD-normalized revenue versus $891M for TLX. In operating R&D and SG&A reinvestment, NAMS deploys N/A (0 90-day corporate R&D disclosures) versus 41.4% of Rev ($369M) (0 disclosures) for TLX.
TLX screens cheaper on headline valuation multiples. NAMS trades at 108.7x Forward P/E, 108.7x Trailing P/E, N/M PEG, and 76.0x EV/Revenue (unreported FCF margin), whereas TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NAMS (-30.2% ROE) versus TLX (7.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NAMS carries 202.2% implied volatility (54th %ile, Balanced (25th–60th %ile)), a 5.06x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 68% Vol realized risk). By comparison, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.